within Pharmacolibrary.Drugs.ATC.D;

model D01AE24
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 1.8 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 444 / 1000000,
    adminCount     = 1,
    Vd             = 0.022,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Tavaborole is a topical antifungal agent used to treat onychomycosis (fungal infection of the toenails or fingernails) in adults. It acts by inhibiting leucyl-tRNA synthetase, thereby disrupting protein synthesis in fungal cells. It is an FDA-approved treatment for onychomycosis of the toenails caused by Trichophyton rubrum or Trichophyton mentagrophytes.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated in healthy adults based on available FDA label and review information. No published studies report quantitative compartmental pharmacokinetic models for tavaborole in humans.</p><h4>References</h4><ol><li><p>Zane, LT, et al., &amp; Gupta, AK (2015). Tavaborole topical solution, 5% for the treatment of toenail onychomycosis. <i>Drugs of today (Barcelona, Spain : 1998)</i> 51(10) 599–607. DOI:<a href=&quot;https://doi.org/10.1358/dot.2015.51.10.2401004&quot;>10.1358/dot.2015.51.10.2401004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26583302/&quot;>https://pubmed.ncbi.nlm.nih.gov/26583302</a></p></li><li><p>Jinna, S, &amp; Finch, J (2015). Spotlight on tavaborole for the treatment of onychomycosis. <i>Drug design, development and therapy</i> 9 6185–6190. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S81944&quot;>10.2147/DDDT.S81944</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26640371/&quot;>https://pubmed.ncbi.nlm.nih.gov/26640371</a></p></li><li><p>Elewski, BE, &amp; Tosti, A (2014). Tavaborole for the treatment of onychomycosis. <i>Expert opinion on pharmacotherapy</i> 15(10) 1439–1448. DOI:<a href=&quot;https://doi.org/10.1517/14656566.2014.921158&quot;>10.1517/14656566.2014.921158</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24856836/&quot;>https://pubmed.ncbi.nlm.nih.gov/24856836</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D01AE24;
